Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
5.74
+0.10 (1.77%)
Mar 5, 2026, 4:00 PM EST - Market closed
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Aardvark Therapeutics stock have an average target of 19.63, with a low estimate of 6.00 and a high estimate of 50. The average target predicts an increase of 241.99% from the current stock price of 5.74.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Aardvark Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 3 |
| Buy | 3 | 3 | 5 | 5 | 5 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $35 → $21 | Buy | Maintains | $35 → $21 | +265.85% | Mar 2, 2026 |
| BTIG | BTIG | Strong Buy Maintains $26 → $9 | Strong Buy | Maintains | $26 → $9 | +56.79% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 2, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $29 → $7 | Buy → Hold | Downgrades | $29 → $7 | +21.95% | Mar 2, 2026 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $24 → $6 | Strong Buy → Hold | Downgrades | $24 → $6 | +4.53% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
278.18K
EPS This Year
-3.00
from -5.15
EPS Next Year
-3.93
from -3.00
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 3.2M | ||||
| Avg | n/a | 278,185 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.82 | -3.24 | ||||
| Avg | -3.00 | -3.93 | ||||
| Low | -3.06 | -5.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.